BMS takes over Amira
Following the acquisition, Amira has become the wholly-owned subsidiary of BMS. Earlier in July 2011, BMS signed a definitive agreement to acquire Amira for $325m. The deal allowed
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.